Genentech - Database of Clinical Trials by Pharmaceutical Companies

Paid Clinical Trials and Focus Groups


Find Paid Clinical Trials

Paid Clinical Trials - : Genentech

Top of Directory » All Categories » by Company » Genentech



  • Radiosurgery and Avastin for Recurrent Malignant Gliomas

    Condition:   Malignant Glioma
    Interventions:   Radiation: Radiosurgery;   Drug: Bevacizumab
    Sponsors:   Duke University;   Genentech
    Not yet recruiting - verified November 2009
  • Ranibizumab Therapy for Choroidal Neovascularization (CNV) Asociated With Angioid Streaks

    Condition:   Angioid Streaks
    Intervention:   Drug: ranibizumab
    Sponsors:   University of Illinois;   Genentech
    Not yet recruiting - verified November 2009
  • A Pilot Study of Bevacizumab (Avastin) in Patients With Unresectable or Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease

    Conditions:   Hemangioblastomas;   Von Hippel Lindau Disease
    Intervention:   Drug: Avastin
    Sponsors:   Dartmouth-Hitchcock Medical Center;   Genentech
    Not yet recruiting - verified November 2009
  • A Study of RO5072759 With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia

    Condition:   Lymphocytic Leukemia, Chronic
    Interventions:   Drug: RO5072759;   Drug: rituximab;   Drug: chlorambucil
    Sponsors:   Hoffmann-La Roche;   Genentech
    Not yet recruiting - verified November 2009
  • Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

    Condition:   Brain and Central Nervous System Tumors
    Interventions:   Biological: bevacizumab;   Drug: temozolomide;   Genetic: gene expression analysis;   Other: laboratory biomarker analysis;   Procedure: adjuvant therapy;   Radiation: external beam radiation therapy
    Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified November 2009
  • Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion

    Conditions:   Branch Retinal Vein Occlusion;   Central Retinal Vein Occlusion;   Retinal Vein Occlusion;   Depression
    Intervention:   Drug: ranibizumab (Lucentis)
    Sponsors:   Retina Associates of Cleveland, Inc;   Genentech
    Recruiting - verified November 2009
  • Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma

    Condition:   Squamous Cell Carcinoma
    Intervention:   Drug: Tarceva, Torisel
    Sponsors:   University of New Mexico;   Genentech
    Not yet recruiting - verified November 2009
  • Effects of Growth Hormone on Cognition and Cerebral Metabolism in Adults

    Condition:   Hypopituitarism
    Intervention:   Drug: Human Growth hormone - nutropin
    Sponsors:   Stanford University;   Genentech
    Recruiting - verified November 2009
  • Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases

    Conditions:   Metastatic Breast Cancer;   Breast Cancer;   Progressive Breast Cancer
    Interventions:   Drug: carboplatin;   Drug: bevacizumab;   Drug: herceptin
    Sponsors:   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Massachusetts General Hospital;   Beth Israel Deaconess Medical Center;   Genentech
    Recruiting - verified October 2009
  • Avastin/Radiation (XRT)/Temozolomide Followed by Avastin/Temozolomide/Topotecan for Glioblastoma

    Conditions:   Malignant Glioma;   Glioblastoma Multiforme;   Gliosarcoma
    Intervention:   Drug: Avastin in Combination with Radiation and Temozolomide followed by Avastin, Temozolomide, and Topotecan
    Sponsors:   Duke University;   Genentech;   GlaxoSmithKline
    Not yet recruiting - verified October 2009
  • The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge

    Condition:   Cat Allergy
    Interventions:   Drug: Omalizumab;   Drug: Placebo
    Sponsors:   Johns Hopkins University;   National Institute of Allergy and Infectious Diseases (NIAID);   Genentech
    Recruiting - verified October 2009
  • Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein Occlusions

    Condition:   Retinal Vein Occlusion
    Interventions:   Drug: Ranibizumab .5mg;   Drug: Ranibizumab .5mg with laser;   Drug: Ranibizumab 2.0 mg;   Drug: Ranibizumab 2.o dose with laser
    Sponsors:   Johns Hopkins University;   Genentech
    Not yet recruiting - verified October 2009
    • Menu
    Find Paid Clinical Trials